Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Active Lupus Nephritis

NCT05609812 is registered in ClinicalTrials.gov with Vera Therapeutics, Inc. as lead sponsor.

NCT NCT05609812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05609812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Active Lupus Nephritis
Lead sponsor
Vera Therapeutics, Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
November 2, 2022
Completion date
December 15, 2028
Enrollment
0 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis (ln)